Switching to guselkumab for adults with active IBD after ustekinumab

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a multi-center observational study in Canada following adults who start guselkumab as their treating doctor decides. Participants receive guselkumab according to local medical guidelines and clinicians may adjust treatment as part of routine care. Researchers will monitor symptoms, laboratory and endoscopy results, and overall health over one year. The goal is to see whether switching from ustekinumab to an IL-23 inhibitor provides better symptom control without worsening key test results.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Subjects of any gender aged ≥ 18.
* Confirmed diagnosis of IBD (CD, UC, or IBDU) for at least 6 months prior to baseline visit. Subjects with IBDU will be grouped with subjects with UC. The CD proportion of patients will be capped at 75%.
* Subjects have received ustekinumab for at least 14 weeks and who are currently on or recently discontinued ustekinumab therapy.
* For subjects that have recently discontinued ustekinumab, the last dose of ustekinumab must have been within 12 weeks before Week 0, and no other advanced therapy (i.e., infliximab, adalimumab, golimumab, certolizumab pegol, vedolizumab, natalizumab, risankizumab, mirikizumab, tofacitinib, upadacitinib, ozanimod, etrasimod) was started since stopping ustekinumab.
* Subjects with an inadequate response to ustekinumab who require a change in advanced therapy and are initiating guselkumab, as determined by the treating physician.
* For subjects on off-label ustekinumab dosing (90 mg every 4 or 6 weeks (off-label dosing), enrollment will be capped at 60%.
* Ability and willingness to give written informed consent and comply with the requirements of this study protocol.
* Subjects who have evidence of ongoing endoscopic evidence of disease activity within 3 months prior to Week 0, defined as:

  * For Crohn's Disease: Colonoscopy showing SES-CD score (excluding the presence of narrowing component) of ≥6 (or ≥4 for participants with isolated ileal disease), OR presence of ulcers larger than 5 mm in any segment.
  * For Ulcerative Colitis: Colonoscopy showing Ulcerative Colitis Endoscopic Index of Severity (UCEIS) score ≥4, OR presence of erosions or ulcers in any segment.

Exclusion Criteria:

* History of prior exposure to any anti-p19 inhibitor (risankizumab or mirikizumab).
* Subjects with formal contraindication to guselkumab per the drug label.
* Use of guselkumab for an off-label indication, dosing regimen, or route of administration. Subjects who did not receive guselkumab induction will be excluded.
* Subjects with an ostomy or ileo-anal pouch.
* Subjects with a history of bowel surgery within 6 months prior to Week 0.
* Subjects displaying clinical signs of acute severe UC, fulminant colitis or toxic megacolon within 3 months prior to Week 0.
* Subjects who are expected to require bowel surgery by their IBD physician within the year of enrollment.
* Subjects on 1 or more concomitant biologics.
* Subjects with a history of colonic dysplasia (low-grade dysplasia, high-grade dysplasia, or colorectal cancer). Note: Patients with a history of indefinite for dysplasia would be eligible.
* Subjects with formal contraindication or unwilling to undergo lower endoscopy.
* The patient is considered by the Investigator, for any reason, to be an unsuitable candidate for the study.

Where it's running

• University of Calgary
  Calgary, Alberta, Canada Recruiting
• MA MacMillan
  Fredericton, New Brunswick, Canada Recruiting
• Barrie GI Associates
  Barrie, Ontario, Canada Recruiting
• Brampton Gastroenterology Research Group Inc
  Brampton, Ontario, Canada Recruiting
• GNRR Digestive Clinics and Research Center Inc.
  Brampton, Ontario, Canada Recruiting
• LDDI Clinical Trials Inc. dba London Digestive Disease Institute
  London, Ontario, Canada Recruiting

Study contacts

• Principal investigator: Laura E. Targownik, MD, MSHS, FRCPC — TIDHI Innovation Inc.
• Study coordinator: Ajani Jeyakumar, HBSc BScN RN
• Email: ajeyakumar@tidhi.ca
• Phone: 647-812-2113

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Wearable data to spot IBD flareups in people with ulcerative colitis or Crohn's disease

  This study tests whether heart‑rate variability from participants’ own wearables can help predict IBD flares.

  Recruiting at 2 sites Maastricht University Medical Center · 's-Hertogenbosch and 2 other locations · NCT07647640

• Reducing ustekinumab dosing for Crohn's disease and ulcerative colitis

  This will try giving ustekinumab less often—changing from every 4 or 8 weeks to every 8 or 12 weeks—to see if people with Crohn's disease or ulcerative colitis in deep remission can stay well.

  Recruiting Phase 4 McGill University Health Centre/Research Institute of the McGill University Health Centre · Montreal, Quebec · NCT07303686

• Reducing ultra-processed foods in children and teens with IBD

  This project will test whether short nutrition handouts or handouts plus a brief video can help children and teens with IBD eat fewer ultra-processed foods.

  Recruiting Connecticut Children's Medical Center · Hartford, Connecticut · NCT07224113

• SMART-IBD app for teens with inflammatory bowel disease

  This will test whether the SMART-IBD smartphone app helps adolescents ages 13–17 with IBD take their medicines and manage symptoms better than completing daily diaries alone.

  Recruiting Children's Hospital Medical Center, Cincinnati · Cincinnati, Ohio · NCT07195123

• TIDHI Healing Circuits mental health program for people with IBD

  This study tests whether Healing Circuits™ delivered by a social worker or via a self-guided online program helps adults with IBD who have moderate anxiety or depression.

  Recruiting TIDHI Innovation Inc. · North York, Ontario · NCT07013578

• Optimizing Infliximab Treatment for Inflammatory Bowel Disease

  This study is testing a new way to give infliximab to adults with moderate-to-severe inflammatory bowel disease who haven't improved with steroids, to see if personalized dosing can help them feel better.

  Recruiting Pontificia Universidad Catolica de Chile · Santiago · NCT06758024

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.